Stay updated on Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial page.

Latest updates to the Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedA minor revision update is shown: Revision: v3.3.2 has been added, replacing the previous Revision: v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check15 days agoChange DetectedA new revision stamp (v3.3.1) was added and the previous revision (v3.2.0) removed, with no changes to study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check23 days agoChange DetectedRemoved the government funding and site operation status notice that previously appeared on the page.SummaryDifference0.4%

- Check37 days agoChange DetectedNo substantive changes were detected; updates appear administrative. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check66 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference2%

- Check73 days agoChange DetectedUpdated the revision from v3.0.2 to v3.1.0; no other content changes observed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial page.